Attached files
| file | filename |
|---|---|
| 10-Q - FORM 10-Q - VALEANT PHARMACEUTICALS INTERNATIONAL | a55998e10vq.htm |
| EX-15.1 - EX-15.1 - VALEANT PHARMACEUTICALS INTERNATIONAL | a55998exv15w1.htm |
| EX-32 - EX-32 - VALEANT PHARMACEUTICALS INTERNATIONAL | a55998exv32.htm |
| EX-31.1 - EX-31.1 - VALEANT PHARMACEUTICALS INTERNATIONAL | a55998exv31w1.htm |
| EX-31.2 - EX-31.2 - VALEANT PHARMACEUTICALS INTERNATIONAL | a55998exv31w2.htm |
Exhibit 15.2
May 3, 2010
Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Commissioners:
We are aware that our report dated May 3, 2010 on our
review of interim financial information of Valeant
Pharmaceuticals International (the “Company”) for the
three-month periods ended March 31, 2010 and 2009 and
included in the Company’s quarterly report on
Form 10-Q
for the quarter ended March 31, 2010 is incorporated by
reference in its Registration Statements on
Form S-4
(File
No. 333-165277),
Form S-3
(File
No. 333-112904)
and
Form S-8
(File Nos.
33-56971,
333-81383,
333-73098,
333-85572,
333-109877,
333-109879,
333-142651,
333-156931
and
333-160393.
Very truly yours,
/s/ PricewaterhouseCoopers
LLP